toxylact: a04ad05 metopimazine

The first professional lActological database in the word

Metopimazine (ATC A04AD05) is a phenothiazine antiemetic that acts predominantly as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone and peripheral D2 sites, and its use in lactation requires a cautious, individualized risk–benefit assessment due to limited direct human data.medpedia.framar+4

Pharmacological class and indications

Metopimazine belongs to the phenothiazine group of antiemetics, with prominent antidopaminergic activity.sciencedirect+3
Clinically it is used to prevent and treat nausea and vomiting, particularly chemotherapy‑induced nausea and vomiting (CINV), acute gastroenteritis–related emesis, postoperative nausea, and other gastrointestinal disorders causing nausea.synapse.patsnap+3

Metopimazine is marketed in Europe, Canada and South America under brand names such as Vogalene/Vogalen, with multiple oral, rectal and intravenous formulations, and is an active ingredient in nationally approved medicinal products though not centrally approved by EMA or FDA.guidetopharmacology+1

Mechanism of action and pharmacodynamics

Metopimazine exerts its antiemetic effect primarily through antagonism of dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and at peripheral D2 sites in the gastrointestinal tract.synapse.patsnap+3
By blocking D2 receptors, it reduces CTZ activation by emetogenic stimuli and modulates gastrointestinal motility, thereby diminishing the intensity and frequency of nausea and vomiting.medpedia.framar+2

Experimental and clinical pharmacology also indicate some affinity for serotonin 5‑HT3 and histamine H1 receptors, which may contribute to its broader antiemetic profile and sedation potential.synapse.patsnap+1

Pharmacokinetics and formulations

Metopimazine is available as capsules, orally disintegrating tablets, suppositories, oral liquid, and intravenous solution, allowing flexible use in ambulatory and oncology settings.wikipedia
The approved daily dose in French oral products is typically around 30 mg/day, divided into multiple doses, with IV formulations used mainly for CINV in adults and children.sciencedirect+1

Pediatric pharmacokinetic data show that orally administered metopimazine achieves plasma concentrations compatible with antiemetic efficacy in children with acute gastroenteritis, supporting its frequent clinical use in this population.bpspubs.onlinelibrary.wiley

Efficacy and clinical use

In chemotherapy‑induced nausea and vomiting, adding metopimazine to ondansetron or ondansetron plus prednisolone significantly increases the proportion of patients with no acute emesis compared with ondansetron alone, with response rates around 63–78% versus 47–50% for monotherapy.sciencedirect
Metopimazine combined with prednisolone appears less effective than granisetron in some acute CINV settings, but still provides clinically meaningful antiemetic protection.sciencedirect

Beyond CINV, metopimazine is widely prescribed in France for general nausea and vomiting, including pregnancy‑related emesis and gastroenteritis, reflecting its established position as a dopamine‑blocking antiemetic.pubmed.ncbi.nlm.nih+1

Adverse effects and toxicity profile

Documented adverse reactions include allergic reactions with rash or urticaria, extrapyramidal symptoms such as parkinsonism, dystonia and rarely malignant neuroleptic syndrome, sedation, endocrine disturbances (gynecomastia in men, galactorrhea and amenorrhea in women), hypotension, blurred vision, photophobia, constipation and urinary retention.medpedia.framar+1
In clinical experience, sedation, orthostatic hypotension and anticholinergic effects are among the more commonly reported adverse events, while extrapyramidal dyskinesias are described as uncommon but potentially serious.medpedia.framar+1

As a phenothiazine derivative, metopimazine shares class‑related neuroleptic and endocrine risks, including the potential for hyperprolactinemia and neuroleptic malignant syndrome, particularly at higher doses or in susceptible patients.guidetopharmacology+2

Pregnancy and reproductive safety

A large observational cohort using the EFEMERIS database evaluated 135,574 pregnant women, of whom 11,402 (8.2%) were exposed to metopimazine, predominantly in the first trimester.pubmed.ncbi.nlm.nih
No association was found between first‑trimester exposure and major birth defects (adjusted odds ratio approximately 1.06, 95% CI 0.92–1.23), and pregnancy loss was actually negatively associated with metopimazine use (adjusted hazard ratio about 0.80, 95% CI 0.72–0.88).pubmed.ncbi.nlm.nih

Rates of prematurity, low birth weight and small‑for‑gestational‑age infants were comparable between exposed and unexposed women, and the authors concluded that available data do not indicate a teratogenic effect or increased risk of pregnancy loss, while emphasizing that formal efficacy and safety trials in pregnant women remain lacking.pubmed.ncbi.nlm.nih

Lactation: general principles and extrapolated risk

There are currently no robust, direct quantitative data on metopimazine excretion into human breast milk or systematic lactation safety studies for this specific drug.sps+1
However, its pharmacological class, molecular characteristics and clinical experience with related dopamine‑blocking antiemetics (e.g., metoclopramide, phenothiazines such as prochlorperazine and promethazine) inform a cautious, extrapolated toxicological‑lactological assessment.e-lactancia+2

For several antiemetics, short‑term use in breastfeeding is considered acceptable with careful monitoring of the infant for sedation, gastrointestinal symptoms and feeding difficulties, and with attention to maternal safety (e.g., extrapyramidal effects and mood changes).nhs+1

Potential effects on the breastfed infant

Based on its mechanism and class, potential infant risks from metopimazine exposure via breast milk include:

·        Central nervous system depression: drowsiness, decreased arousal, or impaired feeding behavior, related to D2 antagonism and sedative H1 activity.sps+3

·        Extrapyramidal or neuromotor effects: theoretically dystonia, abnormal movements or altered tone, although such events are rare even with therapeutic infant doses of dopamine antagonists.sps+2

·        Gastrointestinal symptoms: possible constipation or mild digestive discomfort related to anticholinergic effects and dopaminergic modulation of gut motility, similar to occasional GI complaints reported with metoclopramide in breastfed infants.nhs+2

Given the lack of quantitative milk transfer data for metopimazine, any suspected infant effect (excessive sleepiness, poor feeding, abnormal movements, or persistent GI symptoms) should prompt immediate clinical review and reconsideration of therapy.nhs+1

Potential effects on lactation and maternal endocrine status

Phenothiazine dopamine antagonists can raise serum prolactin, potentially promoting or sustaining lactation in some women, but the clinical magnitude and consistency of this effect with metopimazine are not characterized.e-lactancia+3
Conversely, chronic dopamine blockade may contribute to menstrual disturbances, galactorrhea and other endocrine phenomena, which could complicate lactation and maternal reproductive health if high doses or long‑term courses are used.e-lactancia+2

Because other dopamine‑blocking agents such as metoclopramide have been deliberately used as galactagogues but later discouraged due to maternal and infant risk concerns, any extrapolated use of metopimazine to influence milk production should be avoided outside specialist supervision.e-lactancia+1

Clinical use in breastfeeding mothers: risk–benefit framework

For breastfeeding women with severe nausea and vomiting (e.g., CINV, postoperative nausea, or severe gastroenteritis) where metopimazine is being considered, the following principles can guide risk–benefit evaluation:

·        Indication and necessity: reserve metopimazine for situations where non‑pharmacological measures and safer, better‑studied antiemetics in lactation are ineffective or unsuitable, and where effective emesis control is critical to maternal health and continuation of breastfeeding.sps+1

·        Dose and duration: use the lowest effective dose for the shortest feasible duration to minimize cumulative infant exposure via breast milk, avoiding prolonged or high‑dose therapy whenever possible.wikipedia+2

·        Infant factors: avoid or be extremely cautious in preterm or medically fragile infants, in whom CNS depression or extrapyramidal toxicity would be less tolerable, and prefer alternative antiemetics with more favorable lactation data.sps

Routine co‑sleeping should be avoided when the mother uses sedating medications due to increased risk of sudden unexpected death in infancy, a precaution that applies to metopimazine as a potentially sedating phenothiazine antiemetic.sps

Lactation‑oriented monitoring and counselling

If metopimazine is used during breastfeeding, targeted monitoring should be implemented:

·        Infant monitoring: observe for changes in feeding pattern, weight gain trajectory, alertness, unusual sleepiness, abnormal movements, or gastrointestinal symptoms such as constipation or abdominal discomfort; promptly reassess therapy if such signs appear.nhs+1

·        Maternal monitoring: screen for extrapyramidal symptoms, mood changes, sedation, orthostatic hypotension and endocrine disturbances (e.g., galactorrhea, menstrual irregularities), and adjust dose or consider switching to an alternative antiemetic as needed.medpedia.framar+2

Counselling should emphasize that the evidence base for metopimazine in lactation is limited, that safer alternatives may exist depending on indication, and that shared decision‑making with the patient is essential, especially in oncology or complex medical contexts.sciencedirect+1

Preferred alternatives and positioning in lactation safety

Current lactation guidance for antiemetics (based largely on UK NHS specialist pharmacy service recommendations) highlights several agents with more characterized breastfeeding safety profiles, such as cyclizine, hyoscine hydrobromide, metoclopramide, ondansetron, prochlorperazine and promethazine, used short‑term with caution and infant monitoring.nhs+1
Metopimazine, lacking comparable lactation data, should generally be considered a second‑line or specialist‑use option in breastfeeding, reserved for cases where its particular efficacy or clinical familiarity outweighs the uncertainties regarding infant exposure.guidetopharmacology+2

From a toxicological‑lactological perspective, metopimazine fits into the broader category of dopamine‑blocking antiemetics requiring individualized assessment, careful dosing and structured monitoring when used in breastfeeding mothers, rather than routine first‑line selection.medpedia.framar+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.